• LAST PRICE
    13.9900
  • TODAY'S CHANGE (%)
    Trending Up0.2200 (1.5977%)
  • Bid / Lots
    13.6000/ 1
  • Ask / Lots
    14.4800/ 1
  • Open / Previous Close
    13.8100 / 13.7700
  • Day Range
    Low 13.7400
    High 14.0400
  • 52 Week Range
    Low 7.3600
    High 17.1950
  • Volume
    159,085
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 13.77
TimeVolumeKNSA
09:32 ET311314.01
09:39 ET10013.82
09:42 ET72013.835
09:44 ET46613.87
09:46 ET10013.86
09:48 ET20013.875
09:51 ET39413.925
09:53 ET50013.85
09:55 ET547913.94
09:57 ET10013.93
10:00 ET10013.96
10:06 ET10013.96
10:09 ET271513.965
10:11 ET10014
10:13 ET43314
10:15 ET30014.005
10:18 ET30014.025
10:20 ET180014.015
10:22 ET20013.98
10:26 ET185613.9524
10:27 ET40013.92
10:31 ET30013.87
10:33 ET10013.84
10:36 ET20013.86
10:38 ET20013.81
10:40 ET40013.8
10:42 ET10013.81
10:45 ET146813.83
10:47 ET40013.8
10:49 ET40013.82
10:51 ET10013.82
10:56 ET20013.81
10:58 ET48213.83
11:02 ET105413.855
11:03 ET30013.82
11:05 ET20013.83
11:09 ET10013.81
11:18 ET10013.81
11:20 ET10013.815
11:21 ET35813.7888
11:25 ET30013.74
11:30 ET15713.74
11:32 ET60013.78
11:34 ET15013.7601
11:36 ET20013.775
11:41 ET20013.78
11:43 ET120013.81
11:45 ET71413.82
11:48 ET40013.83
11:57 ET31013.85
12:01 ET10013.835
12:06 ET10013.835
12:08 ET190213.82
12:10 ET834513.89
12:12 ET20013.93
12:14 ET44613.93
12:17 ET30013.975
12:19 ET155713.935
12:26 ET20013.935
12:28 ET24913.919
12:32 ET30013.92
12:35 ET29413.91
12:37 ET11213.935
12:39 ET30013.935
12:42 ET20013.91
12:46 ET10013.89
12:48 ET30013.92
12:51 ET24513.915
12:55 ET10013.915
12:57 ET33013.91
01:00 ET10013.91
01:02 ET106013.91
01:04 ET31913.91
01:06 ET54813.91
01:11 ET10013.94
01:22 ET10013.925
01:24 ET10013.9338
01:26 ET130713.905
01:27 ET160013.92
01:31 ET80013.935
01:38 ET10013.93
01:42 ET30013.95
01:45 ET10013.94
01:47 ET29013.938
01:49 ET93013.94
01:51 ET21013.9241
01:56 ET20013.93
01:58 ET30013.945
02:00 ET10013.96
02:02 ET80013.97
02:03 ET15813.97
02:05 ET10013.95
02:07 ET22013.9617
02:09 ET10013.98
02:12 ET33213.98
02:14 ET40013.955
02:20 ET20013.92
02:21 ET20013.89
02:23 ET20013.88
02:27 ET30013.895
02:30 ET20013.89
02:32 ET40013.87
02:34 ET70013.885
02:43 ET10013.88
02:45 ET70013.89
02:50 ET20013.88
02:52 ET41013.8962
02:54 ET10013.9
02:56 ET110013.89
02:59 ET60013.88
03:01 ET17113.875
03:03 ET169413.87
03:06 ET60013.865
03:10 ET10013.84
03:12 ET572513.88
03:14 ET50013.9
03:15 ET60013.92
03:17 ET100013.92
03:19 ET10013.92
03:21 ET10013.95
03:30 ET20013.955
03:32 ET40013.96
03:35 ET40013.97
03:37 ET30013.95
03:39 ET60013.95
03:42 ET30013.975
03:44 ET73313.97
03:46 ET106813.965
03:48 ET30013.965
03:50 ET30013.98
03:51 ET160013.99
03:53 ET77813.97
03:55 ET244713.94
03:57 ET316113.9588
04:00 ET2852113.99
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
972.7M
7.0x
---
United StatesEXAI
Exscientia PLC
824.5M
-6.6x
---
United StatesALBO
Albireo Pharma Inc
912.3M
-6.6x
---
United StatesRAPT
Rapt Therapeutics Inc
966.0M
-11.0x
---
United StatesIGMS
IGM Biosciences Inc
962.7M
-4.0x
---
United StatesMIRM
Mirum Pharmaceuticals Inc
880.1M
-20.9x
---
As of 2023-01-29

Company Information

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s portfolio of assets includes ARCALYST (rilonacept), Mavrilimumab, Vixarelimab and KPL-404. The Company's ARCALYST is an interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for treatment of recurrent pericarditis (RP), cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS), and muckle-wells syndrome (MWS) in adults and children. Its Mavrilimumab is a monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα). Its Vixarelimab is a monoclonal antibody inhibitor of signaling through oncostatin M receptor beta (OSMRβ). Its KPL-404 is a monoclonal antibody inhibitor of CD40-CD154 interaction.

Contact Information

Headquarters
Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Sanjiv Patel
Chief Financial Officer, Senior Vice President
Mark Ragosa
Chief Operating Officer, Senior Vice President
Eben Tessari
Senior Vice President and Chief Commercial Officer
Ross Moat
Senior Vice President and Chief Medical Officer
John Paolini

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$972.7M
Revenue (TTM)
$177.0M
Shares Outstanding
69.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.11
EPS
$2.00
Book Value
$2.68
P/E Ratio
7.0x
Price/Sales (TTM)
5.5
Price/Cash Flow (TTM)
6.7x
Operating Margin
-18.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.